InnovAge First Quarter 2027 Earnings Conference Call - INNOVAGE HOLDING CORP

Financial Performance:

• Revenue reached $264.8 million, up 12.1% year-over-year (YoY), driven by a 6.7% increase in census and higher capitation rates.
• Center-level contribution margin increased to $63.6 million (24% of revenue), a 230 basis point improvement from 21.8% in the prior year quarter.
• Adjusted EBITDA grew 75% to $31.3 million (11.8% margin), compared to $17.6 million (7.5% margin) in Q1 2026.
• Net income improved to $20.9 million from $7.7 million, with EPS at $0.14.
• External provider costs rose 6.3% to $115.7 million, though cost per participant decreased due to reduced assisted living and nursing facility utilization.
• De novo losses narrowed significantly to $0.1 million from $4.3 million in the prior year quarter.
• Balance sheet ended with $119.3 million in cash and cash equivalents plus $43.7 million in short-term investments, with total debt at $61.4 million.
• Operating cash flow was positive at $28.7 million, with $3 million in capital expenditures.

Guidance and Future Outlook:

• Reaffirmed full fiscal 2027 guidance: Census of 8,625–8,850, member months of 101,000–102,500, revenue of $1.05–$1.085 billion, and Adjusted EBITDA of $105–$115 million.
• Projected Medicare rate increases of 1.5% to 2.0% effective January 1, 2027, which already factor in the V-28 risk adjustment transition.
• Forecasted full-year de novo losses between $0.4 million and $0.8 million.
• Management expects continued quarterly seasonality, with Q1 historically being the strongest due to rate updates and prior to full merit increase impacts, followed by moderation in Q2 and Q3.
• Long-term target Adjusted EBITDA margin remains in the "10% plus" range.

Business Segments and Product Lines:

• Census growth primarily driven by strong performance in California, Colorado, and Florida centers.
• Launched "Innovate 3.0" strategy focusing on clinical capabilities, technology (including Epic integration), AI adoption for administrative efficiency, and center-led accountability.
• Investing in in-house specialists (e.g., cardiology) and network partnerships to reduce assisted living and nursing facility (ALF/NIF) utilization.
• Insourcing pharmacy services continues to yield cost savings.
• Exploring growth beyond existing centers via de novo expansion in new markets, acquisitions, and strategic partnerships/adjacencies (e.g., upstream populations or downstream managed care integrations).

Market and Competitive Landscape:

• PACE participants are distinct from typical Medicare Advantage (MA) plans, being nursing-home eligible with higher medical complexity and frailty, which impacts risk scoring under V-28.
• PACE payment model includes a unique "frailty factor" that recognizes functional limitations, mitigating the impact of V-28 diagnosis weighting changes.
• Management notes increased investor interest in the PACE model following a recent secondary offering that expanded the public float.
• Competitive advantage cited includes established infrastructure, multi-state operating experience, and strong government payer relationships.

Risks and Challenges:

• V-28 risk adjustment model transition creates uncertainty regarding "softer codes" (e.g., stable angina, vascular disease) which may see reduced weighting, though high-severity conditions (CHF, COPD, ESRD) remain weighted.
• Seasonal volatility in enrollment (Medicare Open Enrollment pressure in Q3) and medical costs (respiratory illness peaks in Q2).
• Potential headwinds from annual payroll tax resets, health insurance benefit cost increases, and potential Medicaid rate negotiation delays (e.g., California rates expected in ~3 weeks).
• Dependence on external provider networks; failure to align incentives could impact cost containment.

Management Commentary and Tone:

• Tone is confident and cautious, emphasizing the "durability" of progress with 13 consecutive quarters of positive momentum.
• Management stressed that Q1 results do not imply annualizing growth due to inherent seasonality and the need for measured caution.
• Leadership expressed satisfaction with the successful secondary offering, viewing it as validation of the PACE model's value proposition.
• Executives highlighted a strategic shift from pure organic growth to selectively pursuing M&A and adjacencies once operational rigor is proven.

Analyst Questions and Answers:

• V-28 Impact: Q1 confirmed V-28 impact is manageable due to high patient acuity; 45% of revenue is Medicare, and the frailty factor provides a buffer.
• State Rates: California rates expected in ~3 weeks; management remains conservative in budgeting; Colorado rates are being negotiated but align with expectations.
• Cost Per Participant: External provider cost per participant decreased; attributed to network management, in-house specialists, and better care coordination keeping patients out of ALF/NIF.
• Growth Adjacencies: No specific transactions announced; focus is on cultivating relationships for future M&A, de novo expansion, and applying the PACE model to non-eligible populations.
• Margin Guidance: The implied margin step-down in subsequent quarters reflects seasonal normalization (risk score decay, rate resets) rather than performance deterioration; target is sustained 10%+ margins.

Other Key Points:

• The recent secondary offering was an affiliated shareholder sale (11.5 million shares); InnovAge received no proceeds, but the transaction improved liquidity and broadened the institutional investor base.
• Management plans to leverage AI specifically for clinical decision support and administrative burden reduction, avoiding investments that do not improve care or lower costs.
• Center-led approach remains central to the strategy, with enterprise resources being aligned to empower local center leaders.
• The "frailty factor" in the PACE payment model is highlighted as a key differentiator protecting revenue against V-28 diagnosis weighting changes.